CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02609984
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:39.833305+00:00
Published At: 2020-05-14T00:00:00+00:00
Record Updated At: 2020-07-07
Results Posted At: 2020-05-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Sarcoma", "Myxoid/Round Cell Liposarcoma", "Synovial Sarcoma", "Metastatic Sarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Locally Advanced Sarcoma", "Liposarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-07-07"
protocolSection.identificationModule.nctId: "NCT02609984"
protocolSection.identificationModule.officialTitle: "A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-05-14"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.